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Abstract 
Although BMP4-induced differentiation of glioma stem cells is well 
recognized, details of the cellular responses triggered by this morphogen are still 
poorly defined. In this study we established several glioma stem cell-enriched cell 
lines (GSC-ECLs) from high grade gliomas. The expansion of these cells as 
adherent monolayers, and not as floating neurospheres, enabled a thorough study 
of the phenotypic changes that occurred during their differentiation. Herein, we 
evaluated GSC-ECLs behavior towards differentiating conditions by depriving them 
of growth factors and/or by adding BMP4 at different concentrations. After 
analyzing cellular morphology, proliferation and lineage marker expression we 
determined that GSC-ECLs have distinct preferences in lineage choice, where 
some of them showed an astrocyte fate commitment and others a neuronal one. 
We found that this election seems to be dictated by the expression pattern of BMP 
signaling components present in each GSC-ECL. Additionally, treatment of GSC-
ECLs with the BMP antagonist Noggin also led to evident phenotypic changes. 
Interestingly, under certain conditions some GSC-ECLs adopted an unexpected 
smooth muscle-like phenotype. As a whole, our findings illustrate the wide 
differentiation potential of glioma stem cells, highlighting their molecular complexity 
and paving a way to facilitate personalized differentiating therapies.  
 
Key words: cancer stem cells; multipotency; differentiation; glioblastoma; BMP4; 
Noggin 
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Introduction  
Gliomas are the most frequent primary brain tumors in adults (13). They are 
classified as astrocytoma, oligodendroglioma, or ependymoma, based on the glial 
cell type that predominates in the tumor (28). Among gliomas, glioblastoma 
multiforme (GBM) is a diffusely and rapidly growing tumor with distinctive 
histological features. Despite aggressive multimodal therapies consisting of 
surgical resection, radiotherapy, and chemotherapy, the median survival in GBM is 
less than 15 months (48). Although their cell heterogeneity is well described, the 
initial malignant transformation events and the cell type involved in the origin of 
these tumors are still unclear (46). The hypothesis stating that a subset of cells 
within the tumor, named cancer stem cells (CSCs), initiate and maintain tumor 
growth leading to a hierarchy of cells within GBM is now well accepted (9). The 
most recent form of the CSC model includes the concept of ‘dynamic stemness’, 
hypothesizing an interchange between CSCs and more-differentiated cells 
(progenitors) (24). In this sense, emerging findings support the existence of a 
contextually regulated equilibrium between CSCs and transit amplifying neoplastic 
progenitors, including the capacity of progenitor cells dedifferentiation to form 
CSCs (24). 
These CSCs have functional similarities to normal neural stem cells (NSCs) 
including their clonogenicity and capability for multi-lineage differentiation (27, 46). 
Defined gradients of signaling factors coordinate self-renewal and differentiation in 
NSCs populations during neural development. Genetic alterations or epigenetic 
regulation of genes that disturb this delicate balance in NSCs and restricted 
progenitors may lead to development of brain tumors (53).  A
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Bone morphogenetic proteins (BMPs) are a family of growth factors that 
mediate a wide variety of biological responses in NSC, ranging from proliferation 
and differentiation to apoptosis depending on the NSC developmental stage as 
well as the milieu of the local microenvironments (7, 25). It has been reported that 
BMP2/4 acts as a neuroepithelial proliferation signal at very early stages of 
embryonic central nervous system (CNS) development, an effect mediated 
principally by the Bone Morphogenetic Protein Receptor type IA (BMPRIA) (11, 
35). Later in development, BMP2/4 induces neuronal and astrocytic differentiation 
of NSCs, an event that occurs via the Bone Morphogenetic Protein Receptor type 
IB (BMPRIB) (16, 29). In the adult brain stem cell niche, BMPs have an instructive 
role that favors the acquisition of an astroglial fate. Interestingly, a pro-
differentiation BMP response mechanism seems to be preserved in some glioma 
CSCs. Furthermore, these cells express BMPRs, and BMP family ligands inhibit 
their proliferation. Importantly, transient in vitro exposure to BMP4 abolishes the 
capacity of transplanted GBM cells to establish intracerebral GBMs (38). However, 
BMPs RNA transcript production is regulated via promoter methylation/ 
hypermethylation and several reports have demonstrated that BMP gene 
methylation is associated with downregulated expression in different types of 
cancer (20, 52). Remarkably, epigenetic-mediated dysfunction of BMPR1B in a 
subset of GBM represses the pro-differentiation effects of BMPs (23). 
While BMP signaling activation is crucial for many events in development, its 
inhibition is equally necessary for others. As a result, there are a number of 
extracellular and intracellular mechanisms that block the influence of BMP 
signaling. BMP actions are regulated in vivo by proteins such as Noggin, Follistatin, A
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Chordin, and Neurogenesin which antagonize BMPs activities by directly binding to 
BMPs ligands (6, 42). The endogenously secreted BMP antagonist, Noggin, limits 
BMP signaling below the gliogenic threshold and redirects normal stem cells to 
generate neurons (26). Therapy forcing glioma CSCs to differentiate might be a 
promising and notably non-cytotoxic strategy for CSC targeting. In this regard 
BMPs may be potential soluble factors in the treatment of gliomas (38).  
In the present study, we established six glioma stem cell-enriched cell lines 
(GSC-ECLs) from tumor biopsies that exhibited cancer stem/progenitor cells 
properties and initiated tumor formation following xenotransplantation. We further 
demonstrated that not all GSC-ECLs responded equally to a particular 
differentiation stimuli. However, we found that BMP4 treatment decreased 
proliferation of all tested GSC-ECLs to a similar extent, even in the presence of 
mitogens. 
As a whole, in the present study we determined that GSC-ECLs exhibit 
distinct preferences in lineage choice and possess a broad phenotypic plasticity 
which can be regulated by external factors. Moreover, the expressed phenotype 
may be largely determined by the interplay between the competence of the 
receiving cell (genetic and epigenetic signatures of individual GSC-ECL) and the 
signaling emerging from the surrounding microenvironment (niches). Therefore, 
further knowledge of the mechanisms that govern this interplay is needed to better 
control tumor growth. 
 
Materials and Methods  
Tissue samples A
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This study is in compliance with the October 2013 Helsinki Declaration and it has 
been approved by the Biomedical Research Ethics Committee “Comité de Ética en 
Investigaciones Biomédicas de la Fundación para la Lucha contra Enfermedades 
Neurológicas de la Infancia (FLENI)”, and written informed consent was received 
from each patient whose tumor tissue was used for this project.  
Fresh tumor specimens used for this study were surgically resected at FLENI. After 
resection, samples were snap-frozen and stored at -80°C. These sections were 
classified morphologically and graded according to WHO criteria by experienced 
neuropathologist (NA and GES). 
 
Nucleic acid isolation 
Fresh frozen human tissues from brain tumors or GSC-ECLs were used to extract 
high-molecular genomic DNA using DNeasy kit extraction (Qiagen, Valencia, CA, 
USA). Purified DNA was quantified by ultraviolet absorbance at 260 nm and DNA 
quality was assessed by electrophoresis on 1% agarose gels. 
 
Genomic analysis 
Genomic DNA was extracted from 1 to 5 mg frozen tissue or glioma-derived cells 
(2x106) as described above. Samples were quantified spectrophotometrically, and 
5 ng of DNA were used in each determination. Loss of heterozigosity (LOH) was 
assessed by the QuMA method (32) using Applied Biosystems 7500 Real-Time 
PCR system. The following markers were studied: D1S468, D1S214 and D1S199 
for 1p loss and D19S596, D19S408 and D19S867 for 19q loss. Markers for LOH at 
10q were D10S536 (located near the phosphatase and tensin homolog, PTEN, A
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gene) and D10S1683 (mapping close to deleted in malignant brain tumors 1, 
DMBT-1, gene). Homozygous deletions in the cyclin-dependent kinase inhibitor 2A 
(CDKN2A/ARF) gene were detected following a published protocol (3). Epidermal 
growth factor receptor (EGFR) gene amplifications were assessed in a multiplex 
real-time reaction employing the same conditions described for CDKN2A/ARF, 
including Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as reference 
gene. Primers for the EGFR gene have the following sequences: forward 5′-
GAAGCTTGCTGGTAGCACTTG-3′ and reverse 5′-
GTGGAAGCCTTGAAGCAGAAC-3′; the probe has the following sequence: 5′-
6FAMCCCAACTGTGAGCAAGGAGCACATAMRA-3′. TP53 gene mutations 
(exons 5 to 8) were detected by direct sequencing using primers already described 
(47) and confirmed by direct sequencing. Isocitrate dehydrogenase 1 (IDH1), 
mutation screening was carried out according to the recently published method 
(30). O6-methylguanine-DNA methyltransferase (MGMT) methylation-specific PCR 
Methylation status of MGMT gene was determined and validated by methylation-
specific PCR (MSP) as previously described (34).  
 
EGFRvIII detection 
Total RNA was extracted from 50-100 mg of each frozen tumor specimen using 
TRIzol reagent (Invitrogen) in a tissue grinder and then treated with amplification 
grade DNase I for 15 minutes at 37°C. For each sample, 1 µg of total RNA was 
reverse transcribed using Superscript II (Invitrogen) with oligo(dT) priming 
according to the manufacturer's protocols. 2 µl of 1st strand cDNA (1/10th of the 
reverse transcription reaction volume) was then used as template in a 50 µl PCR A
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reaction containing 2 mM MgSO4, 0.2 μM of each primer, 0.2 mM dNTPs, 1x High 
Fidelity PCR Buffer, and 1 unit of Platinum Taq High Fidelity (Invitrogen). 
Forward and reverse primer sequences to specifically amplify EGFR and EGFRvIII 
were 5' CTTCGGGGAGCAGCGATGCGA C 3' (spanning the 5’ untranslated 
region and the beginning of exon 1) and 5' ACCAATACCTATTCCGTTACAC 3' 
(within exon 9), respectively. Cloned wild type EGFR and EGFRvIII cDNAs were 
used as templates in parallel positive control reactions, alongside reverse 
transcription and PCR negative control reactions. GAPDH was also amplified for 
each sample to assess relative RNA template quality and amount. Primers for 
GAPDH were 5’ GTGAAGGTCGGAGTCAACGG 3’ and 5’ 
TGATGACAAGCTTCCCGTTCTC 3’. 
  
Histological characterization  
Biopsies from xenografts were processed for paraffin embedding and 10 µm thick 
sections were stained for Hematoxylin and Eosin. After deparaffinization, sections 
were microwaved in 10 mM sodium citrate buffer (pH 6.0) for 10 minutes and 
incubated with the primary antibody anti-GFAP (1:500, AB5804) (Millipore, 
Billerica, MA, USA), over night at 4C°. Antigen retrieval procedure was performed 
using citrate buffer and the microwave technique. Replacement of the primary 
antibody with phosphate buffer served as a negative control. Subsequently, slides 
were incubated with the appropriate secondary antibody and then with 
streptavidin/biotin peroxidase complex. Diaminobenzidine served as chromogen. 
Ki-67 labeling of paraffin embedded sections was made with monoclonal antibody 
Ki67 (1:100, NCL-Ki67-MM1) (Novocastra Laboratories, Newcastle, UK). Briefly, A
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sections were deparaffinized, then placed in 300 ml of 10 mM citrate buffer (pH 
6.0) and heated five times for 3 min each at full power in a 500-W microwave oven 
to activate the Ki-67 protein epitope. After heating, sections were reacted for 12 h 
with the primary antibody diluted 1:50 in phosphate-buffered saline containing 1% 
normal rabbit serum, stained by the avidin-biotin complex method, developed with 
methyl-green. More than 1000 cells were counted in several section areas that 
were as representative as possible of the pathological feature. Ki-67 labeling index 
was calculated as the percentage of positively stained nuclei.  
 
Culture of human glioma-derived cells 
Brain tumor cultures were established as soon as possible (20–30 min) after 
surgery by mechanical disaggregation of biopsies followed by accutase (Invitrogen, 
Carlsbad, CA, USA) incubation for 15 minutes at 37°C. Next, the cellular 
suspension was centrifuged for 5 minutes at 200x g. The resultant pellet was 
resuspended in serum-free medium consisting of Neurobasal medium 
supplemented with B27, N2, 20 ng/ml basic fibroblast growth factor (bFGF), 20 
ng/ml epidermal growth factor (EGF), 2 mM L-glutamine, 2mM non-essential amino 
acids, 50 U/ml penicillin/streptomycin (all from Invitrogen, Carlsbad, CA, USA), 
20µg/ml bovine pancreas insulin and 75 µg/ml low-endotoxin bovine serum 
albumin (Sigma, St. Louis, MO, USA) and plated onto laminin coated plates (10 
ug/ml) (Sigma, St. Louis, MO, USA). Cells were routinely grown to confluence, 
dissociated using accutase and then splitted 1:2 to 1:3. Medium was replaced 
every 2–3 days.  A
cc
ep
te
d 
A
rti
cl
e
10 
This article is protected by copyright. All rights reserved. 
To induce differentiation the same Neurobasal medium devoid of bFGF and EGF 
(growth factor withdrawal) was used. When indicated growth factor-deprived 
medium was supplemented with 0.5 ng/ml or 10 ng/ml human recombinant BMP4 
and/or 250 ng/ml Noggin (R&D Systems, Minneapolis, MN, USA). Medium was 
replaced every 3–4 days.  
 
Glioma stem cell-enriched cell lines transplantation 
The tumorigenic potential of the cell lines was tested by orthotopic transplantation 
of 105 cells into the caudate-putamen of immunodeficient mice. All applicable 
international, national, and institutional guidelines for the care and use of animals 
were followed. Surgical procedures were carried out under general anesthesia with 
IP ketamine (0.1 mg/g body weight). We used 5‐8 week old nude (nu/nu) mice. 
Mice were sacrificed within the first 4 months post-implantation. From each brain 
tumor sample several slices were cut, fixed and embedded in paraffin for 
pathological studies.  
 
Immunostaining and fluorescent microscopy 
Lineage and proliferation markers were analyzed by fluorescent microscopy. 
Briefly, cells were rinsed with ice-cold PBS containing Ca2+ and Mg2+ and fixed in 
PBSA (PBS with 0.1% bovine serum albumin) with 4% formaldehyde for 45 min. 
After two washes, cells were permeabilized with 0.1% Triton X-100 in PBSA with 
10% normal goat serum for 30 min, washed twice and stained with the 
corresponding primary antibodies. Fluorescent secondary antibodies were used to 
locate the antigen/primary antibody complexes. Cells were counterstained with 4, 
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6-diamidino-2-phenylindole (DAPI) and examined under a Nikon Eclipse TE2000-S 
inverted microscope equipped with a 20X E-Plan objective and a super high-
pressure mercury lamp. The images were acquired with a Nikon DXN1200F digital 
camera, which was controlled by the EclipseNet software (version 1.20.0 build 61). 
The following primary antibodies were used: anti-Sox2 (1:100, ab59776), anti-
CD44 (1:100, ab19657) (Abcam Inc., Cambridge, UK); anti-Vimentin (1:200, 
M0725) (Dako, Glostrup, Denmark); anti-Nestin (1:200, AB5922) (Chemicon 
International Inc., Temecula, CA, USA); anti-GFAP (1:500, AB5804) (Millipore, 
Billerica, MA, USA); anti-MAP2 (1:500, M1406); anti-α-Smooth muscle Actin 
(1:100, 1A4) (Sigma, St. Louis, MO, USA); anti-Ki67 (1:100, NCL-Ki67-MM1) 
(Novocastra Laboratories, Newcastle, UK).  
 
Cell counting 
Cells were counted in 6-8 random fields under inverted fluorescent microscope: 
Nikon Eclipse TE2000-S at 200x magnification, per experimental condition. The 
number of single- or double-stained cells was expressed as a percentage of the 
total DAPI-stained cell population.  
 
Reverse Transcription Polymerase Chain Reaction 
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) 
according to manufacturer’s instructions. cDNA was synthesized using MMLV 
reverse transcriptase (Promega, Madison, WI, USA) from 500 ng of total RNA. The 
cDNA samples were diluted fivefold and the PCR reaction was conducted at an 
annealing temperature of 60°C. Reactions were within the linear range of A
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amplification. Quantitative PCR studies were carried out using SYBR® Green-ERTM 
qPCR SuperMix UDG (Invitrogen, Carlsbad, CA, USA) and the primer sequences 
used are the following: CD133 sense 5'-ACAACACTACCAAGGACAAGG-3', 
antisense 5' GGACTTAATCTCATCAAGAACAGG-3'; GFAP sense 5'-
AGGAAGATTGAGTCGCTGGAG-3', antisense 5'-CGGTGAGGTCTGGCTTGG-3'; 
MAP2 sense 5'-CAGGAGACAGAGATGAGAATTCCTT-3', antisense 5'-
GTAGTGGGTGTTGAGGTACCACTCTT-3'; h-Caldesmon sense 5'-
TGGAGGTGAATGCCCAGAAC-3', antisense 5'-GAAGGCGTTTTTGGCGTCTTT-
3'; Calponin-1 sense 5'-CTGTCAGCCGAGGTTAAGAAC-3', antisense 5'-
GAGGCCGTCCATGAAGTTGTT-3'; Transgelin sense 5'-
AGTGCAGTCCAAAATCGAGAAG-3', antisense 5'-CTTGCTCAGAATCACGCCAT-
3'; BMPR1A sense 5'-AGATGACCAGGGAGAAACCAC-3', antisense 5'-
CAACATTCTATTGTCCGGCGTA-3'; BMPR1B sense 5'-
GGAGCAGTGATGAGTGTCTAAGG-3', antisense 5'-
TGCCCACAAACAGAAGAGTACC-3' and GAPDH sense 5'-
ACAGCCTCAAGATCATCAG-3', antisense 5'-GAGTCCTTCCACGATACC-3'. All 
samples were analyzed using an ABI PRISM 7500 Sequence Detector System (PE 
Applied Biosystems, Foster City, CA, USA) and were normalized to gapdh gene 
expression. 
  
Flow Cytometric Analysis  
Single-cell suspensions were obtained by treatment with accutase (37°C for 5min). 
Cells (1x106) were incubated with monoclonal CD133/1 (AC133)-PE conjugate 
antibody (1:11, 130-080-801) (Miltenyi Biotec, Auburn, CA, USA) in PBS containing A
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0.5% bovine serum albumin and 2 mM EDTA for 10 min at 4°C and washed with 2 
ml of PBS. Cells were then centrifuged at 300 x g for 5 min, resuspended in 0.5 ml 
PBS and analyzed by flow cytometry. 
Data was acquired on a FACSAria II flow cytometer from Becton Dickinson (BD 
Biosciences, San Jose, USA) and analyzed using WinMDI 2.9 software. 
Background fluorescence was estimated by substituting the specific primary 
antibody with specific isotype controls.  
 
Determination of cell doubling time  
Proliferation rates were compared on the basis of doubling time. GSC-ECLs  were 
plated in parallel at 100,000 or 200,000 cells per well in 6 well plates. After 7 and 
14 days cells were enzymatically dissociated and counted using a hemacytometer. 
The increase in cell number compared to the initial number of cells was used to 
calculate the doubling time by assuming an exponential growth model. The two 
plating densities were chosen in order to minimize any effect of density dependent 
cell growth. 
 
Western Blotting 
Cells were lysed in ice-cold RIPA buffer supplemented with a protease inhibitor 
mixture, and protein concentration was determined using the Bicinchoninic Acid 
Protein Assay (Pierce™, Rockford, IL, USA). Equal amounts of protein were run on 
12 % polyacrylamide gel electrophoresis, and transferred to PVDF-FL membrane 
(Millipore, Billerica, MA, USA). The membrane was blocked for 1 h in Odyssey A
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blocking buffer (LI-COR Biosciences, Lincoln, NE, USA) containing 0.1% Tween 20 
and then incubated overnight at 4°C in a solution containing Odyssey blocking 
buffer, 0.05% Tween 20 and the corresponding primary antibodies. The membrane 
was washed 4 × 5 min with Tris-buffered saline (TBS), 20 mM Tris-HCl, pH 7.5, 
500 mM NaCl)  containing 0.1% Tween 20 (TTBS), then incubated for 1 h in a 
solution containing Odyssey blocking buffer, 0.2% Tween 20, and IR-Dye 
secondary antibodies (1:20.000, LI-COR Biosciences, Lincoln, NE, USA) and 
subsequently washed 4 × 5min in TTBS, 1 × 5min in TBS. The membrane was 
immediately scanned for protein bands using the 680nm and 780 nm channels at a 
scanning intensity of 4. Immunocomplexes were visualized using the Odyssey 
Infrared Imaging System (LI-COR). The following primary antibodies were used: 
anti-Actin (sc-1616; Santa Cruz, CA, USA), anti-BMPRIA (ABD51; Millipore, 
Billerica, MA, USA) Antigen/primary antibody complexes were detected with near 
infrared-fluorescence-labeled, IR-Dye 800CW or IR-Dye 680RD, secondary 
antibodies (LI-COR Biosciences, Lincoln, NE, USA). 
Alternatively, after electrophoresis the separated proteins were transferred to a 
PVDF membrane (Bio-Rad, Hercules, CA, USA). Blots were blocked 1 h at room 
temperature in TTBS containing low-fat powdered milk (5%). Incubations with 
primary antibodies were performed at 4 °C for 12 h in blocking buffer (3% skim milk 
in TTBS). The membranes were then incubated with the corresponding counter-
antibody and the proteins evidenced by enhanced chemiluminescence detection 
(SuperSignal West Femto System, Thermo Scientific, Rockford, IL, USA). The 
following primary antibodies were used: anti-Actin (sc-1616, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), anti-BMPR1B (SAB1403613; Sigma, St. A
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Louis, MO, USA). The following secondary antibodies were used: a horseradish 
peroxidase-conjugated α-rabbit IgG; α-mouse IgG or α-goat IgG. 
 
BMP4 measurements 
The concentration of BMP4 in the culture supernatants was determined using a 
specific Enzyme-Linked Immunosorbent Assay kit (# RAB0029, Sigma, St. Louis, 
MO, USA) following the manufacturer’s instructions. Briefly, 4x105 cells were 
seeded onto 24-well culture dishes and 300ul of medium per well were 
conditionated for 24 hs.  
 
Results 
GSC-ECLs conserve the genetic and epigenetic abnormalities present in 
their parental tumors, express neural/stem cell markers and initiate tumor 
formation following xenotransplantation 
In this study, we isolated cells from high grade human glioma biopsies and 
cultured them as monolayers on laminin-coated plates in the presence of a glioma 
stem-permissive medium which contains EGF and bFGF (40). Currently, it is well 
accepted that under these conditions cultures are enriched in glioma stem cells 
(22). To test their long-term self-renewal capacity these cell lines were 
continuously passaged in vitro for more than one year. During this period GSC-
ECLs retained their particular growth rate and morphology. The six established 
GSC-ECLs were named G02, G03, G05, G07, G08 and G09. All of them were 
derived from GBM samples. Basic demographic and clinical characteristics of each 
patient are described in table 1. A
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To elucidate whether the glioma derived cell lines were representative of 
their parent tumors at the molecular level, we evaluated several genetic and 
epigenetic alterations that are currently determined as part of the routine clinical 
interrogation of gliomas. To address this issue, we first evaluated codon 132 point 
mutations of the IDH1 gene. Then, to further assess accumulation of genetic 
anomalies linked to tumor suppressor inactivation or mitogen hyperactivation, we 
analyzed CDKN2A/ARF gene homozygous deletion, LOH at 10q (associated to 
PTEN and DMBT-1 inactivation), TP53 gene mutations, EGFR gene amplification 
and presence of truncated EGFR variant mutation (EGFRvIII). Additionally, we 
determined the LOH for both 1p and 19q using at least three polymorphic markers 
on 1p and 19q each. Finally, promoter methylation status of the DNA repair gene 
that encodes the O6-methylguanine-DNA methyltransferase (MGMT) was 
examined. As shown in table 2, our data confirmed that the derived cell lines highly 
conserved the genomic and epigenomic profiles of their parent tumors except for 
the observed EGFR amplifications. In accordance with previous reports, EGFR 
gene copies were decreased in almost all tested GSC-ECL with respect to the 
corresponding original tumor, suggesting that in vitro culture in the presence of 
recombinant EGF (20 ng/ml) selects against EGFR genetic lesions (44). 
Importantly, in this sense, no changes in G02 cell line were observed where 
chromosomal gain of the EGFR gene (trisomy 7) was detected. 
Within the last few years, many efforts have been aimed to identify cell 
surface markers useful for prospective isolation of CSCs. Among these, much 
attention has been given to CD133/prominin-1, a cholesterol-binding membrane 
protein of unknown biological function. Currently, CD133 is used to enrich CSCs A
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from brain tumors (2, 38). Here, we evaluated CD133 transcript levels by 
quantitative RT-PCR analysis and found that they were highly variable among the 
tested GSC-ECLs (Fig. 1a, top panel). In all cases, flow cytometry analysis 
confirmed a strong correlation between CD133 mRNA levels and protein 
abundance and showed that in each cell line the fraction of positive cells ranged 
from 2.90±0.02% in G02 to 80.02±0.04% in G09 (Fig. 1a, mid and bottom panels). 
Importantly, it has been reported that certain high grade glioma-derived CD133 
negative cells also display CSC properties, questioning the role of this trans-
membrane protein as a unique marker of brain CSCs and highlighting the need for 
more specific markers (33). 
Currently, to further draw the stemness signature of CSCs, the use of 
multiple markers such as the components of intermediate filaments, Nestin and 
Vimentin, the transmembrane glycoprotein, CD44, and the transcription factor sex 
determining region Y-box 2 (Sox2), is accepted. To ascertain whether glioma-
derived cells have similarities to NSCs we undertook a phenotypic characterization 
of the isolated GSC-ECLs. By immunocytochemistry we determined the presence 
of the aforementioned NSC/neural progenitor markers. Nearly all cells within the 
cultures express Nestin, Vimentin, CD44 and Sox2 (Fig. 1b). Then, to test the 
capacity of GSC-ECLs to initiate tumor formation, 105 cells/mouse were injected 
into the right putamen of immunocompromised mice. After 2-4 months, mice were 
sacrificed revealing the formation of brain lesions exhibiting features of gliomas, 
which included human GFAP expression and a high proliferation index (Fig. 1c). A
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Finally, we estimated the doubling time of each GSC-ECL. Notably, a wide 
variation among cell lines was determined, which ranged from 2.97±0.18 days in 
G09 cells to 10.54±1.2 days in G05 cells (Fig. 1d). 
 
GSC-ECLs exhibit distinct differentiation behaviors in vitro  
Forcing differentiation of glioma stem cells may represent a potential 
effective therapeutic strategy; thus, it becomes increasingly important to 
understand how molecular signaling regulates differentiation of these cells. BMP4 
is known to participate in the astrocytic differentiation of neural progenitor/stem 
cells (5). However, it has been reported that lineage choice of certain NSCs 
depends in part on BMPs concentrations (10). Therefore, to gain insight into GSC 
multipotent capacity, we exposed the six GSC-ECLs to three defined differentiating 
conditions that include: 1) growth factor (EGF and bFGF) withdrawal; 2) growth 
factor withdrawal plus BMP4 addition at low concentrations (0,5 ng/ml) and 3) 
growth factor withdrawal plus BMP4 addition at high concentrations (10 ng/ml). 
Initially, to identify the phenotypes developed by these GSC-ECLs under the 
mentioned differentiating conditions, we stained cells with the astroglial marker, 
GFAP and with the neuronal marker, β-III-tubulin. Although in several reports this 
combination was used to follow-up both astroglial and neuronal differentiation (22, 
23, 45), we found that GFAP was often co-expressed with β-III-tubulin, reflecting 
the abnormality of the glioma stem/progenitor cells phenotypes (14). Due to this 
aberrant expression, this double staining technique was ineffective to perform cell 
type identification (data not shown). After several approaches, we found that the 
combination of GFAP and MAP2 resulted more appropriate to discriminate cell A
cc
ep
te
d 
A
rti
cl
e
19 
This article is protected by copyright. All rights reserved. 
lineages. To this end, cells were counted according to their GFAP and MAP2 
immunoreactivity and grouped as: GFAP-/MAP2-; GFAP+/MAP2+; GFAP+/MAP2- 
and GFAP-/MAP2+. Despite a considerable percentage of GFAP+/MAP2+ cells 
were detected in some cases, this methodology allowed us to establish a tight 
correlation between lineage markers and morphology.  
The six established GSC-ECLs exhibited different morphological aspects 
and underwent overt and distinct morphological changes after differentiation 
occurred. As detailed in table 3 and in figures 2 and 3, variations of recombinant 
BMP4 concentration (none; 0,5 ng/ml or 10 ng/ml) particularly influenced the 
differentiation outcome of each tested cell line. As expected, in some GSC-ECLs 
(G05 and G07) increasing concentrations of BMP4 favored the acquisition of an 
astroglial phenotype (GFAP+ cells with a star-shaped and branched morphology) 
and prevented the appearance of neuronal-like cells (MAP2+ cells with small 
cellular bodies and thin processes). In contrast, in G08 and G09 GSC-ECLs, cells 
only acquired an astrocyte-like fate upon growth factor removal or in the presence 
of low concentrations of BMP4 (0,5 ng/ml). It should be noted that in these cases, 
the addition of 0,5 ng/ml BMP4 further enhanced the astrocyte morphology and 
reduced the percentage of MAP2+ cells. High concentrations of BMP4 (10 ng/ml), 
instead of promoting an astrocytic morphology, lead to the generation of 
homogeneous GFAP+ cellular populations which displayed a flat and enlarged in 
size morphology. In these GSC-ECLs BMP4 also impaired neuronal differentiation 
in a concentration dependent manner. On the other hand, G03 cells under all 
differentiating conditions adopted an elongated cell shape with large and flat 
cytoplasm, similar to the one observed in G08 and G09 cell lines under high A
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concentrations of BMP4. After differentiation onset, this cell line also displayed an 
increase in the number of GFAP+ cells, which became more evident in the 
presence of high concentrations of BMP4. Additionally, under all culture conditions, 
MAP2+ cells were barely detectable. Finally, G02-differentated cells acquired a 
heterogeneous appearance which was accompanied by an increase in both 
lineage markers. However, in none of these differentiating conditions G02 cells 
adopted a predominant phenotype.  
Remarkably, before subjecting GSC-ECL to differentiating stimuli, we found 
that in several cell lines (G02; G03; G07 and G09) GFAP and MAP2 levels were 
low or undetectable, even though in some of them (G05 and G08) these markers 
were highly expressed. Nonetheless, in these cell lines (G05 and G08) the 
differentiation process was evidenced by dramatic morphological changes. In 
consequence, it should be noted that an increase of lineage marker expression not 
always can be considered as a feature of glioma stem-cell differentiation (Fig. 2 
and Fig. 3). 
The differentiation effects of each experimental condition were also 
evaluated by quantitative RT-PCR analysis. As shown in figure 4a (top panel) the 
expression levels of GFAP mRNA of all GSC-ECLs were significantly induced in 
the tested differentiating conditions, being more pronounced in the presence of 10 
ng/ml recombinant BMP4. This induction correlates with the determined increase in 
the percentage of GFAP+ cells under the corresponding conditions (Fig. 2 and 3, 
right panels). With respect to MAP2 expression levels, we found that in G02, G05 
and G09 cell lines growth factor withdrawal led to an induction of this transcript. 
Conversely, the presence of BMP4 at high concentrations caused a significant A
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decrease in the levels of this mRNA in G03, G07, G08 and G09 cell lines (Fig. 4a, 
bottom panel). This changes are in accordance with the reduction of the 
percentage of MAP2+ cells observed when cells were exposed to recombinant 
BMP4 at 10 ng/ml (Fig. 2 and 3, right panels). 
Finally, by flow cytometry we determined that in G08 and G09 the 
percentage of CD133+ cells diminished at 21 days of differentiation onset (both 
under growth factor withdrawal and under growth factor withdrawal plus BMP4 
addition at 10 ng/ml), although no significant changes were observed in G07 (Fig. 
4b).  
Taken together, these results further demonstrate the well known inter-
tumoral heterogeneity exhibited in high grade gliomas, which was manifested both 
at their undifferentiated state as well as at their differentiation capacity. 
 
Noggin decreases the ratio of GFAP+ to MAP2+ cells in GSC-ECLs  
In line with previous reports (10, 39), we found that in all differentiated GSC-
ECLs, BMP4 addition caused a dose-dependent increase in the number of GFAP+ 
cells and a reduction in the percentage of MAP2+ cells (Fig. 2 and 3, bottom 
panels), supporting the concept that this morphogen is acting as an astroglial 
inducer. However, in the absence of both recombinant BMP4 and growth factors, 
we also detected the appearance of large populations of GFAP+ astrocyte-like cells 
(mainly in G08 and G09 cell lines). Therefore, it stands to reason that this adopted 
phenotype could be due to an autocrine/paracrine BMP signaling. If so, the 
presence of recombinant Noggin would reduce the availability of endogenous A
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BMPs below the gliogenic threshold and allow neuronal differentiation to proceed 
(astroglial-neuronal switch). 
To explore this possibility, we first studied the cellular response triggered in 
G08 and G09 cell lines after Noggin exposure in the absence of mitogens during 
21 days. Interestingly, the presence of Noggin produced a decrease in GFAP 
expression levels, a marked reduction in the percentages of GFAP+ cells, and 
more important, it impaired the appearance of process-bearing star-shaped cells. 
Concomitantly, an increase in the fraction of MAP2+ neuronal-like cells was also 
observed (Fig. 5). Thus, these results suggest that the presence of recombinant 
Noggin could be impairing astroglial differentiation by reducing the action of 
endogenous BMP ligands (e.g. BMP2, BMP4, etc) which might be secreted by 
these GSC-ECLs. In this sense, the mere depletion of growth factors could lead to 
the release of an endogenous BMPs signaling, that in turn will possibly allow 
astrocytic fate commitment. However, it should be noted that growth factor 
withdrawal led to specific lineage choices in each of these six GSC-ECLs (Fig. 2 
and 3), suggesting that the molecular profile of individual GSC-ECL would 
ultimately set the threshold that determines the final phenotype in response to 
differentiating signals coming from tumor microenvironment (niche). 
To gain insight into this phenomenon, and especially considering that G03 
cell line was not able to give rise to MAP2+ cells in any of the assayed 
experimental conditions, we exposed this cell line to recombinant Noggin. Notably, 
in the absence of growth factors, the addition of this BMP antagonist led to the 
appearance of a considerable fraction of MAP2+ cells. However, the majority of 
these MAP2+ cells did not acquire a neuron-like morphology, suggesting that in this A
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cell line, neuronal differentiation is somehow impaired, at least in the assayed 
conditions (Fig. 5, bottom panel). 
Finally, to explore if the observed plasticity can occur in the presence of 
mitogens, we cultured these proliferating GSC-ECLs for 21 days in growth factor-
containing media, supplemented with Noggin (250 ng/ml) or with BMP4 (10 ng/ml). 
As shown in figure 6, in these conditions the presence of Noggin did not produce 
significant changes in cell morphology, although it led to an increase in the fraction 
of MAP2+ cells, which was accompanied by a decrease in GFAP+ population. On 
the contrary, the addition of recombinant BMP4 to growth factor-containing media 
increased the percentage of GFAP+ cells and practically abolished the presence of 
MAP2+ cells. Therefore, even under conditions that allow proliferation (presence of 
bFGF and EGF); the phenotype of these GSC-ECLs can be modulated by the 
status of the BMP signaling network.  
 
Particular GSC-ECLs are capable of adopting a smooth muscle-like 
phenotype 
Neural stem cells display a broad differentiation potential that is not 
restricted to tissues of ectodermal origin but includes muscle and endothelial 
lineages. Such plasticity is lost during the transition from stem to progenitor cells 
and not regained during terminal differentiation (4, 8, 15). Moreover, isolated CNS 
stem cells exposed to novel environments can differentiate into both CNS as well 
as non-CNS fates (4, 15). Thus, differentiation appears to be dependent on the 
environment around stem cells and diffusible signals seem to be important in the 
regulation of fate choice. An example of this is the promotion of cortical stem cell A
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differentiation into alpha smooth muscle actin (α-SMA)-positive cells exerted by 
BMP4 (>10 ng/ml) (10).  
The above considerations, together with the morphological changes (spread 
cells with enlarged cytoplasm) observed in G03 cell lines under all the 
differentiation conditions and in G08 and G09 cell lines in the presence of high 
concentrations of BMP4, prompted us to determine if GSC-ECLs have the potential 
to differentiate into a smooth muscle-like phenotype. To explore this possibility, we 
labeled cells with the cytoskeletal protein, α-SMA. 
The six GSC-ECLs exhibited very dissimilar results with respect to α-SMA 
immunoreactivity. In all tested conditions G02, G05 and G07 cell lines were 
negative for this marker, while G03, G08 and G09 cell lines exhibited different 
percentages of α-SMA+ cells. As shown in figure 7, the morphological changes 
displayed by G03 cell line under all tested differentiation conditions were 
accompanied by the formation of α-SMA fibers. However high doses of BMP4 was 
the only differentiating condition studied that gave rise to significant percentages of 
α-SMA+ cells in G08 and G09 cell lines (Fig. 7a). Finally, by double-labeling 
experiments we determined that a considerable subset of G03 and G09 cells co-
expressed α-SMA and GFAP (Fig. 7b).  
To further characterize the adopted smooth muscle-like phenotype we 
determined the mRNA expression levels of three smooth muscle markers: h-
Caldesmon, Calponin-1 and Transgelin/Smooth muscle protein 22-alpha in G03, 
G05 and G09 cell lines (1, 19, 43). Quantitative RT-PCR analysis revealed a strong 
induction of these three genes in G03 cells under all differentiating conditions as 
well as in G09 cells when differentiated in the presence of high concentration of A
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recombinant BMP4. Notably, the mRNA expression levels of these genes in each 
cell line tightly correlated with their capacity to adopt a smooth muscle-like 
phenotype (Fig. 7c). In fact, G05 cell line, which never adopted a smooth muscle-
like phenotype under the tested differentiating conditions, displayed very low levels 
of these transcripts (Fig. 7c). 
Interestingly, in our initial attempts to identify the cellular phenotypes 
adopted by GSC-ECLs under differentiation conditions, we found that G03 cell line 
maintained a strikingly high percentage of GFAP-/MAP2- cells (Fig 2, bottom 
panel). This behavior was also observed in G09 line under high concentrations of 
recombinant BMP4, in which the percentage of GFAP-/MAP2- cells further 
increased with respect to the other experimental conditions (Fig. 3, bottom panel). 
One explanation for these results could be that under the aforementioned 
conditions these cell lines failed to differentiate. However, as in each cell line the 
percentages of GFAP-/α-SMA+ cells were very similar to those determined 
previously for GFAP-/MAP2- cells, it is reasonable to speculate that a great 
proportion of these double negative populations may actually correspond to the 
herein characterized GFAP-/α-SMA+ fraction (Fig. 7b). 
 
GSC-ECLs reduce their proliferative activity upon exposure to differentiating 
conditions 
The phenotypic diversity displayed by GSC-ECLs subjected to the 
abovementioned differentiation protocols prompted us to explore whether these 
differences would be reflected in their proliferative responses. To address this A
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issue, we measured the Ki67 positive cell fraction in GSC-ECLs exposed to distinct 
experimental conditions by immunostaining. 
As shown in figure 8, in the presence of bFGF and EGF, which favors the 
self-renewal and proliferation of the stem cell compartment, the percentage of 
Ki67+ cells was highly variable, ranging from approximately 30% in G05 cell line to 
67% in G09 cell line. Accordingly, this variability tightly correlates with the doubling 
time of each cell line (Fig. 1d). Importantly, under all tested differentiating 
conditions, a significant reduction in the proliferative ability was determined. 
However, a more pronounced decrease in cell division was achieved after cells 
were treated with 10 ng/ml BMP4, even in the presence of bFGF and EGF. These 
findings suggest that BMP4 itself could counteract growth factor proliferative 
stimuli.  
G09 cell line was the only one whose proliferative activity was tightly 
dependent on bFGF and EGF presence, as we found that Ki67 immunorreactivity 
in growth factor deprived-cells was comparable to the observed in the presence of 
10 ng/ml BMP4. It should be noted that this cell line exhibited neither EGFR gene 
amplification nor EGFRvIII mutation, contrary to what was determined in the rest of 
the GSC-ECLs (Table 2). 
In contrast to the elevated variability observed in GSC-ECLs differentiation 
patterns, we found that recombinant BMP4 treatment (even in the presence of 
bFGF and EGF) led to a similar decrease of cellular proliferation in all tested cell 
lines. This suggests that BMP4 action is accomplished through signals that 
differentially modulate proliferation and differentiation processes. 
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BMP signaling status influences the lineage choice of GSC-ECLs 
To gain insight into the molecular determinants that ultimately dictate the 
lineage choice, we first characterized the expression profile of BMPRs in the six 
isolated GSC-ECLs. By quantitative RT-PCR and Western blot analysis we 
determined that each cell line exhibits a specific expression pattern. We find that all 
undifferentiated cell lines show comparable expression levels of BMPR1A but very 
different expression levels of BMPR1B (Fig. 9a and b and data not shown). These 
differences in BMPR1B abundance prompted us to explore whether the expression 
levels of this receptor change upon differentiation or in response to differentiating 
stimulus. By quantitative RT-PCR analysis we find that, growth factor withdrawal 
and BMP4 addition at a low concentration (0.5 ng/ml) led to the induction of 
BMPR1B transcript levels in all studied cell lines. However, when recombinant 
BMP4 was added at a high concentration (10 ng/ml) different behaviors were 
observed. While in G02, G03 and G05 cell lines BMPR1B mRNA expression levels 
increased, in G07 cell line no appreciable changes were observed. Contrarily, in 
G08 and G09 cell lines mRNA levels were significantly reduced (Fig. 9c). Similar 
results were obtained by Western blotting (Fig. 9d). 
Interestingly, cell lines that expressed higher levels of BMPR1B were the 
ones (G05, G08 and G09) that preferentially adopted an astrocyte-like phenotype 
when differentiated in the absence of growth factors or in the absence of growth 
factors plus BMP4 at a low concentration (0.5 ng/ml) (Fig. 2 and 3). Remarkably, 
under differentiating conditions, where BMPR1B expression levels were induced, 
these cell lines acquired an astrocyte-like phenotype. In contrast, when BMPR1B 
transcript levels were reduced, as observed in G08 and G09 cell lines in the A
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presence of 10 ng/ml BMP4, a smooth muscle-like phenotype was adopted (Fig. 
7a).  
G03 and G07 cell lines express similar low levels of BMPR1B, even though 
they committed to different lineages (smooth muscle-like and neuronal-like 
phenotypes respectively). Thus, their respective BMPR1B expression levels do not 
account for the different phenotypes adopted by these cell lines. In an attempt to 
understand these differences, we measured the abundance of endogenous BMP4 
in undifferentiated GSL-ECLs culture supernatants. Notably, we find that in G03 
cell line, secreted BMP4 was significantly more abundant than in the rest of the 
studied cell lines. This pattern was also observed in growth factor deprived cell 
lines (Fig. 9e). Moreover, a significant increase in the abundance of secreted 
BMP4 was detected in G03, G08 and G09 GSC-ECLs when they were 
differentiated in the absence of growth factors for 21 days (Fig. 9e). The higher 
concentration of endogenous BMP4 determined in G03 cells supernatants 
suggests that the abundance of this morphogen could be responsible, at least in 
part, for the smooth muscle-like phenotype adoption. It is important to note that the 
same molecular setting (high levels of BMP4 and low expression of BMPR1B) was 
present when G08 and G09 cell lines exhibited a smooth muscle-like phenotype 
(Fig. 7a). 
Analyzing this together, we noted a correlation between BMP4 and 
BMPR1B expression levels and the lineage adopted when growth factors were 
removed. While astrocyte-like phenotypes are preferentially adopted by cells that 
express high levels of BMPR1B (G05, G08 and G09 cell lines), smooth muscle-like 
phenotypes are acquired in cells that show low levels of BMPR1B and are exposed A
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to high concentrations of BMP4 (G03 cell line). Finally, a neuronal-like phenotype 
is adopted by G07 GSC-ECL, which expresses low levels of BMPR1B but secretes 
lower amounts of BMP4 than G03 cell line.  
 
Discussion  
Since it has been clearly demonstrated that distinct adult NSCs and 
progenitors exist (49), it is conceivable to think that a particular GSC phenotype 
may account for the cellular origin of the tumor. However, it has been proposed 
that lineage marker expression is not necessarily indicative of the cancer cell of 
origin (21, 56). For instance, it was observed that breast cancer cells displaying a 
phenotype of basal cells would originate from luminal cells (31). Moreover, in some 
cancer cells a certain degree of “phenotypic reversibility” has been determined, 
wherein particular cell types may acquire CSC properties. This phenomenon could 
be induced by microenvironment-secreted growth factors and/or by stress signals 
(51). In gliomas, the induction of the hypoxia-inducible factor 2 alpha (HIF2α) 
transcription factor, which mediates the transcriptional response to hypoxia, has 
been involved in the acquisition of GSC properties and in the up-regulation of 
CD133 expression (17).  
In this work we observed that different GSC-ECLs show particular 
phenotypes. However, we have determined that these cells (under proliferating 
conditions) can change their lineage marker expression pattern and their 
morphology in response to the BMP/Noggin signaling status. Although it is possible 
that tumor cells retain certain phenotypic traits present in the cancer cell of origin, 
these results suggest that the interaction between the molecular setting of each A
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GSC-ECL and the micro-environmental signals plays a key role in the phenotypic 
outcome of a given CSC. Therefore, it should be noted that under particular 
experimental conditions, an in vitro GSC phenotype might be biased. 
As it has been established, BMPs act as potent anti-mitogenic agents in 
GSCs (38). In the present study we further confirm this phenomenon, as all studied 
GSC-ECLs exposed to this morphogen significantly reduced their proliferative 
capacity, even in the presence of mitogens (Fig. 8). Therefore, it is possible to infer 
that the presence of BMP antagonists within the tumor microenvironment could 
favor CSC proliferation. In this sense, Yan and coworkers recently reported that the 
BMP inhibitor, Gremlin1, is secreted in a CSC-specific manner to promote their 
maintenance within the tumor hierarchy (55). 
Although the effect of growth factor withdrawal and/or recombinant BMP4 
addition over cellular proliferation was similar in all tested GSC-ECLs, each of 
these cell lines showed a specific differentiation pattern. While under certain 
conditions some GSC-ECLs gave rise to cultures with high proportions of neuronal-
like cells (G07 and G09), others showed a high tendency to generate astrocyte-like 
cells (G05 and G08). Contrarily, G03 always resulted in homogeneous cell 
populations showing a smooth muscle-like phenotype. Moreover, these cell lines 
displayed cell line specific ranges of phenotypic plasticity, as the adopted 
phenotype was largely dependent on the differentiation conditions, possibly 
reflecting a varying degree of multipotency among different GSC-ECLs. Herein, we 
find that the expression levels of both BMP4 and BMPR1B would be critical 
determinants of the ultimate lineage choice. Importantly, the mere deprivation of 
growth factors led to an increase in the levels of BMPR1B which in some GSC-A
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ECLs (G03, G08 and G09) was accompanied by a rise in the abundance of 
secreted BMP4. These results suggest that the absence of exogenous bFGF and 
EGF could allow the activation of the BMP axis involved in glioma differentiation. In 
this regard, it has been reported that during neural development, FGF signaling 
downregulates BMP4 and BMP7 expression (18, 54) and negatively regulate Smad 
phosphorylation to inhibit downstream BMP signaling(36, 37). 
In parallel with growth of the brain, rapid angiogenesis is necessary to 
supply nutrients and oxygen. Recent studies have shown that neural progenitor 
cells isolated from rat embryonic cerebral cortex can differentiate into smooth 
muscle cells when stimulated with fetal bovine serum, suggesting a contribution to 
the generation of blood vessels in the brain. (50). Additionally, it has been reported 
that lineage choice in cortical NSCs strongly depends on extracellular signals such 
as BMP4, Ciliary neurotrophic factor (CNTF) and Brain-derived neurotrophic factor 
(BDNF) (10). In this publication the authors found that, although low concentrations 
of BMP4 promote both neuronal and astroglial differentiation, higher doses of this 
morphogen lead to development of smooth muscle-like cells. In this regard, we 
also found that BMP4 induces differentiation of GSC-ECLs in a dose-dependent 
manner. For instance, some GSC-ECLs that differentiated into astrocytes or 
neurons in the presence of low doses of BMP4, adopted a smooth muscle-like 
phenotype when exposed to higher doses of this ligand (10 ng/ml). Therefore, 
despite their tumoral nature, these GSC-ECLs seem to preserve certain 
differentiation pathways present in particular NSCs. It is conceivable that under 
specific environmental stimuli, glioma CSCs may activate a latent program of 
smooth muscle differentiation to promote neovascularization and support tumor A
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growth. In fact, Rajan and coworkers described that BMP4 causes the activation of 
at least two distinct cytoplasmic signaling pathways in neural stem cells, one 
mediated by SMAD proteins and the other by signal transducer and activator of 
transcription (STAT) proteins (41). They found that in cultures with low basal levels 
of activated STAT proteins, BMP4 induces smooth muscle differentiation by 
activating Smad1/5/8. Conversely, in cultures that show higher basal levels of 
activated STAT proteins, BMP4 further activates STAT proteins to generate glia at 
the expense of smooth muscle. It will be of interest to see if these signaling 
pathways are operative in glioma CSCs too. If so, the basal levels of activated 
STAT proteins present in each GSC-ECL would be another determinant of cell fate 
choice upon differentiation stimuli.  
Recent evidence suggests that the stem cell fraction of gliomas is radio-
resistant, shows preferential activation of DNA damage checkpoint responses, has 
an increased DNA repair capacity and is enriched following radiation (2). 
Consequently, therapies acting through the induction of apoptosis, which largely 
includes radio and chemotherapies, may have lethal effects on the majority of the 
amplifying cell population but lesser effects on the stem cell-based regenerative 
capacity of tumors. Although differentiation therapy does not directly destroy 
neoplastic stem cells, it restrains their growth and prevents them from generating 
more proliferating or transit amplifying progenitor cancer cells. Thus, forcing tumor 
cells to differentiate constitutes an emerging concept in the search for alternative 
cancer therapies. In this sense, it has been reported that BMP ligands can abolish 
brain cancer stem cell (BCSC) population by inducing stem cells to undergo 
differentiation (38). Notwithstanding, Lee and colleagues (23) found that BMPs A
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facilitate proliferation rather than differentiation in a subset of BCSCs by epigenetic 
silencing of the BMPRIB gene. These distinct responses once more highlight the 
importance of characterizing the molecular features of individual CSCs 
populations. Importantly, in this study we have established that, regardless of their 
molecular signatures, all tested GSC-ECLs markedly reduced their proliferation 
rates when they were exposed to differentiating conditions, mostly in presence of 
high BMP4 concentrations. 
Results presented herein beg the question of how extrinsic signals can 
control CSC fate in such diverse and unexpected ways and highlight the 
importance of this in vitro model. Likewise, the suggestion that BMP4 might be 
explored as a potential therapeutic agent should be viewed with caution given the 
previous demonstration of its mitogenic effects in a subset of BCSCs (23) and our 
findings that, under determined conditions and molecular settings, this morphogen 
may lead to the adoption of phenotypes that might favor tumor sustaining capacity 
(12). The ability to correctly predict the outcome triggered by a differentiating agent 
would influence treatment decisions. Thus, a thorough molecular characterization 
of these patient-derived GSC-ECLs offer the possibility to predict a priori, for 
instance, the effect on the proliferative activity or on the acquisition of a phenotype 
under a particular differentiating therapy, providing a rationale to develop and test 
antineoplastic drugs. Furthermore, the fact that the adoption of a determined 
phenotype can be modulated by endogenous antagonists of the differentiating 
agent further expands this rationale. 
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Table 1. Basic demographic and clinical characteristics of patients 
 
Patient GSC-ECL Sex Age Tumor site (Lobe) 
2 G02 Female 61 Parietal 
3 G03 Male 52 Temporal 
5 G05 Male 52 Temporal 
7 G07 Female 72 Temporal 
8 G08 Female 62 Occipital 
9 G09 Female 59 Frontotemporal 
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Table 2. Genetic and epigenetic alterations in brain tumors and in their respective 
GSC-ELCs.  
 
SAMPLE 
LOH 
10q 
LOH  
1p 
LOH  
19q 
CDKN2A/
ARF 
Deletion 
EGFR 
Amplification 
EGFR 
vIII  
TP53 
Mutation 
MGMT Gene 
Promoter 
Methylation 
IDH1 
Mutation 
G02 
(Biopsy) 
LOH ROH ROH + + (x3) - - + - 
G02 
(GSC-ECL) 
LOH ROH ROH + + (x3) - - + - 
G03 
(Biopsy) 
LOH 
Partial 
LOH 
ROH + + (x55) - - - - 
G03 
(GSC-ECL) 
LOH 
Partial 
LOH 
ROH + + (x4) - - - - 
G05 
(Biopsy) 
LOH ROH ROH + + (x128) + - - - 
G05 
(GSC-ECL) 
LOH ROH ROH + + (x44) + - - - 
G07 
(Biopsy) 
LOH ROH ROH + + (x82) - - - - 
G07 
(GSC-ECL) 
LOH ROH ROH + + (x4) - - - - 
G08 
(Biopsy) 
LOH LOH 
Partial 
LOH 
+ + (x244) - - + - 
G08 
(GSC-ECL) 
LOH LOH 
Partial 
LOH 
+ + (x20) - - + - 
G09 
(Biopsy) 
LOH 
Partial 
LOH 
ROH - - - 
+ 
(R248W) 
- - 
G09 
(GSC-ECL) 
LOH 
Partial 
LOH 
ROH + - - 
+ 
(R248W) 
- - 
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EGFR amplification: estimated number of gene copies is indicated between 
brackets. LOH: Loss of heterozigosity; ROH: Retention of heterozigosity 
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Table 3. Cellular morphology and lineage marker expression of GSC-ECLs 
exposed to distinct experimental conditions. 
 
GSC-
ECL 
+GF -GF -GF + BMP4 (0,5 ng/ml) -GF + BMP4 (10 ng/ml) 
G02 
Homogeneous appearance 
with fusiform cells.  
GFAP
+
 cells:
 
- 
MAP2
+
 cells: - 
Heterogeneous appearance 
without a prevailing 
morphology. 
GFAP
+
 cells: + 
MAP2
+
 cells: + 
Heterogeneous appearance 
without a prevailing 
morphology.  
GFAP
+
 cells: + 
MAP2
+
 cells: + 
Heterogeneous appearance 
without a prevailing 
morphology.  
GFAP
+
 cells: + 
MAP2
+
 cells: + 
G03 
Homogeneous appearance 
with phase-dark cells.  
GFAP
+
 cells:
 
+ 
MAP2
+
 cells: - 
Homogeneous appearance 
with flat cells.  
GFAP
+
 cells:
 
+ 
MAP2
+
 cells: - 
Homogeneous appearance 
with flat cells. 
GFAP
+
 cells:
 
++ 
MAP2
+
 cells: - 
Homogeneous appearance 
with flat cells.  
GFAP
+
 cells:
 
+++ 
MAP2
+
 cells: - 
G05 
GFAP
+
 cells displaying thin 
and long processes: +++ 
MAP2
+
 neuronal-like cells: - 
GFAP
+
 astrocyte-like cells: 
++ 
MAP2
+
 neuronal-like cells: + 
GFAP
+
 astrocyte-like cells: 
++ 
MAP2
+
 neuronal-like cells: + 
GFAP
+
 astrocyte-like cells: 
+++ 
MAP2
+
 neuronal-like cells: - 
G07 
Majority of cells displaying 
small cellular bodies with thin 
processes.  
GFAP
+
 cells: - 
MAP2
+
 cells: + 
GFAP
+
 cells with big 
cytoplasm: - 
MAP2
+
 cells displaying small 
cellular bodies with thin 
processes: +++ 
GFAP
+
 cells with big 
cytoplasm: + 
MAP2
+
 cells displaying small 
cellular bodies with thin 
processes: ++ 
GFAP
+
 astrocyte-like cells: 
+++ 
MAP2
+
 neuronal-like cells: - 
G08 
Three sub-populations in 
similar proportions (GFAP
+
 
large cells, MAP2
+
 tiny cells 
and double positive cells with 
variable morphology). 
GFAP
+
 astrocyte-like cells: 
++  
MAP2
+
 neuronal-like cells: + 
GFAP
+
 astrocyte-like cells: 
+++ 
MAP2
+
 neuronal-like cells: - 
Flat GFAP
+
 cells: +++  
MAP2
+
 cells: - 
G09 
Large GFAP
+
 cells: - 
Small MAP2
+
 cells: +++   
GFAP
+
 astrocyte-like cells: 
++  
MAP2
+
 neuronal-like cells: 
++ 
GFAP
+
 astrocyte-like cells: 
+++ 
MAP2
+
 neuronal-like cells: - 
Flat GFAP
+
 cells: +++  
MAP2
+
 cells: - 
 
–: very low or undetectable percentages; +: low percentages; ++: high 
percentages: +++: very high percentages. GF: Growth factors 
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